

## Special Issue

# Management of Vulvar Cancer

### Message from the Guest Editors

Vulvar cancer (VC) is a rare malignancy, accounting for an estimated 5.6% of all gynecologic malignancies and 3.7% of gynecologic cancer deaths. Ninety percent of primary VCs are squamous cell carcinoma (SCC), while other rare histologies include Bartholin gland adenocarcinoma, melanoma, extra-mammary Paget's disease, verrucous carcinoma, basal cell carcinoma, and sarcoma. Risk factors for the development of vulvar neoplasia include old age, human papillomavirus infection, cigarette smoking, inflammatory conditions, and immunodeficiency. A surgical and reconstructive treatment approach has so far been a cornerstone of the different strategies at both initial and advanced stages. Significant advances have been made over time in pre-operative work-up and surgical planning, turning from 'en-bloc' surgery, which is burdened by the highest morbidity, to more conservative approaches without compromising oncologic safety. Moreover, the integration with other treatments, such as radio-chemotherapy, brachytherapy, or electrochemotherapy, has improved overall clinical outcomes, allowing for additional opportunity even in cases unsuitable for upfront surgery.

---

### Guest Editors

Dr. Giacomo Corrado

Dipartimento Scienze della Salute della Donna, del Bambino, e di Sanità Pubblica, Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

Prof. Giorgia Garganese

1. Gynecology and Breast Care Center, Mater Olbia Hospital, Strada Statale 125 Orientale Sarda, 07026 Olbia, Italy
2. Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, L.go A. Gemelli 8, 00168 Rome, Italy

---

### Deadline for manuscript submissions

closed (31 January 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/66303](https://mdpi.com/si/66303)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)